Pastorczak Agata, Attarbaschi Andishe, Bomken Simon, Borkhardt Arndt, van der Werff Ten Bosch Jutte, Elitzur Sarah, Gennery Andrew R, Hlavackova Eva, Kerekes Arpád, Křenová Zdenka, Mlynarski Wojciech, Szczepanski Tomasz, Wassenberg Tessa, Loeffen Jan
Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, 91-738 Lodz, Poland.
Department of Pediatrics, Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, 1090 Vienna, Austria.
Cancers (Basel). 2022 Apr 14;14(8):2000. doi: 10.3390/cancers14082000.
Patients with double stranded DNA repair disorders (DNARDs) (Ataxia Telangiectasia (AT) and Nijmegen Breakage syndrome (NBS)) are at a very high risk for developing hematological malignancies in the first two decades of life. The most common neoplasms are T-cell lymphoblastic malignancies (T-cell ALL and T-cell LBL) and diffuse large B cell lymphoma (DLBCL). Treatment of these patients is challenging due to severe complications of the repair disorder itself (e.g., congenital defects, progressive movement disorders, immunological disturbances and progressive lung disease) and excessive toxicity resulting from chemotherapeutic treatment. Frequent complications during treatment for malignancies are deterioration of pre-existing lung disease, neurological complications, severe mucositis, life threating infections and feeding difficulties leading to significant malnutrition. These complications make modifications to commonly used treatment protocols necessary in almost all patients. Considering the rarity of DNARDs it is difficult for individual physicians to obtain sufficient experience in treating these vulnerable patients. Therefore, a team of experts assembled all available knowledge and translated this information into best available evidence-based treatment recommendations.
患有双链DNA修复障碍(DNARDs)(共济失调毛细血管扩张症(AT)和尼曼-匹克氏症候群(NBS))的患者在生命的前二十年患血液系统恶性肿瘤的风险非常高。最常见的肿瘤是T细胞淋巴母细胞恶性肿瘤(T细胞急性淋巴细胞白血病和T细胞淋巴母细胞淋巴瘤)和弥漫性大B细胞淋巴瘤(DLBCL)。由于修复障碍本身的严重并发症(如先天性缺陷、进行性运动障碍、免疫紊乱和进行性肺病)以及化疗导致的过度毒性,这些患者的治疗具有挑战性。恶性肿瘤治疗期间常见的并发症包括原有肺病恶化、神经并发症、严重粘膜炎、危及生命的感染和导致严重营养不良的喂养困难。这些并发症使得几乎所有患者都有必要对常用治疗方案进行调整。考虑到DNARDs的罕见性,个体医生很难获得足够的经验来治疗这些脆弱的患者。因此,一组专家收集了所有可用的知识,并将这些信息转化为最佳的循证治疗建议。